WHO – Page 27 – Pharma.Tips

Uncontrolled SOP changes during regulatory inspection – root cause analysis inspectors expect

Addressing Uncontrolled SOP Changes During Regulatory Inspections: A Practical Playbook Regulatory inspections can present significant challenges, particularly when uncontrolled changes to Standard Operating Procedures (SOPs) are identified. Such deviations not…

Poor change control discipline during scale-up – FDA/EMA inspection citation risk

“` Improving Change Control Integrity During Scale-Up to Mitigate Inspection Risks In the pharmaceutical industry, poor change control discipline during scale-up poses significant risks for compliance with Good Manufacturing Practices…

Inadequate GMP training during internal audit – how to rebuild GMP maturity

Addressing Inadequate GMP Training in Internal Audits to Enhance Compliance Maturity Internal audits play a critical role in ensuring compliance with Good Manufacturing Practices (GMP). However, inadequate GMP training during…

Uncontrolled SOP changes during technology transfer – evidence package for inspection defense

“`html Managing Uncontrolled SOP Changes During Technology Transfer: A Playbook for Compliance Uncontrolled Standard Operating Procedure (SOP) changes during technology transfer can create significant risks for pharmaceutical manufacturers, leading to…

Inadequate GMP training during scale-up – evidence package for inspection defense

Understanding and Addressing Inadequate GMP Training During Scale-Up: An Inspection-Ready Playbook In the pharmaceutical manufacturing sector, the critical process of scale-up often highlights gaps in Good Manufacturing Practices (GMP) training.…

Poor change control discipline during regulatory inspection – how to rebuild GMP maturity

Addressing Poor Change Control Practices Pre- and Post-Inspection for GMP Compliance In the highly regulated pharmaceutical industry, poor change control discipline can lead to significant compliance issues during inspections by…

Repeated GMP deviations during scale-up – FDA/EMA inspection citation risk

“`html Addressing Repeated GMP Deviations during Scale-Up to Ensure Inspection Readiness The challenge of managing repeated GMP deviations during scale-up is a critical concern for pharmaceutical manufacturers. Such deviations can…

Inadequate GMP training during technology transfer – CAPA framework to prevent recurrence

Addressing Insufficient GMP Training in Technology Transfer: A CAPA Framework Inadequate GMP training during critical technology transfer phases can significantly impair operational efficiency and compliance. This not only leads to…

Process drift not detected during regulatory inspection – how to rebuild GMP maturity

Addressing Undetected Process Drift During Regulatory Inspections: A Comprehensive Playbook In the pharmaceutical manufacturing landscape, process drift that goes undetected can lead to compliance failures, negative inspection outcomes, and potential…

Inadequate GMP training during internal audit – FDA/EMA inspection citation risk

Managing the Risks of Inadequate GMP Training in Internal Audits In pharmaceutical manufacturing, the robustness of your Good Manufacturing Practices (GMP) training program can significantly impact compliance and overall quality…

Poor change control discipline during scale-up – evidence package for inspection defense

Effective Strategies to Address Poor Change Control during Scale-Up In the pharmaceutical manufacturing arena, the process of scaling up is pivotal yet fraught with the potential for oversight, particularly with…

Repeated GMP deviations during technology transfer – evidence package for inspection defense

Defending Against Repeated GMP Deviations During Technology Transfer Repeated GMP deviations during technology transfer present a significant risk to pharmaceutical companies, compromising product quality, regulatory compliance, and operational efficiency. These…